Galmed Pharmaceuticals Ltd. (GLMD) is a publicly traded Healthcare sector company. As of May 21, 2026, GLMD trades at $0.60 with a market cap of $3.85M and a P/E ratio of 0.00. GLMD moved +7.88% today. Year to date, GLMD is -28.31%; over the trailing twelve months it is -55.91%. Its 52-week range spans $0.41 to $7.76. Analyst consensus is neutral with an average price target of $0.00. Rallies surfaces GLMD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Tissue Dynamics and Galmed Launch 20,000-Organoid Platform for Aramchol Cardiac Fibrosis Research: Tissue Dynamics and Galmed Pharmaceuticals will develop a vascularized, sensor-embedded human cardiac organoid platform to model chronic fibrosis and accelerate Aramchol-based therapeutic research. The DynamiX® system will enable high-throughput monitoring of over 20,000 organoids to assess SCD1-driven lipid metabolism, fibrosis, and tissue repair in post-MI and HFpEF settings.
| Metric | Value |
|---|---|
| Price | $0.60 |
| Market Cap | $3.85M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $7.76 |
| 52-Week Low | $0.41 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
1 analysts cover GLMD: 0 strong buy, 0 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $0.00.